Benitec Receives Final Confirmation of Positive RAC Meeting | GenomeWeb

Benitec Biopharma announced last week that it has received a written report confirming a favorable review of a planned phase I/IIa clinical trial for its expressed hepatitis C treatment from the National Institutes of Health’s Recombinant DNA Advisory Committee.

The company said it made “minor” changes to the study’s protocol after meeting with the committee and has requested a pre-investigation new drug application hearing with the US Food and Drug Administration.

The company expects to begin the trial before the end of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.